<DOC>
	<DOCNO>NCT00507338</DOCNO>
	<brief_summary>ARC1779 novel drug test patient undergo angioplasty stenting primary treatment heart attack .</brief_summary>
	<brief_title>Study ARC1779 Patients With Acute Myocardial Infarction Undergoing PCI</brief_title>
	<detailed_description>Adjunctive anti-thrombotic therapy PCI AMI may improve incorporation novel anti-platelet therapeutic principle , von Willebrand Factor antagonism . ARC1779 therapeutic oligonucleotide ( `` aptamer '' ) block bind A1 domain vWF platelet GPIb receptor , thereby modulate platelet adhesion , activation , aggregation high shear condition coronary arterial stenosis plaque rupture . This study intend provide dose-ranging clinical proof concept ARC1779 primary PCI population .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>troponinpositive NSTEMI , diagnostic symptom and/or ECG abnormality present within precede 24 hour , plan `` early invasive '' management strategy STEMI , plan primary PCI History bleed diathesis evidence active abnormal bleeding within previous 30 day Received treatment fibrinolytic GPIIb/IIIa antagonist drug within precede 72 hour Received anticoagulant therapy low molecular weight heparin within precede 8 hour Severe hypertension ( systolic blood pressure &gt; 200 mmHg diastolic blood pressure &gt; 110 mmHg ) adequately control antihypertensive therapy Major surgery trauma within precede 6 week History stroke within 30 day history hemorrhagic stroke Endstage renal disease ( ESRD ) dependency renal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>percutaneous coronary intervention</keyword>
</DOC>